Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on rare skin diseases, will release its Q3 2026 financial results on November 5, 2026, before market open. The company will hold a conference call at 8:30 a.m. ET the same day to discuss the results and provide a corporate update. Palvella is developing novel therapies including QTORIN™ rapamycin gel and QTORIN™ pitavastatin for rare skin and vascular conditions. Investors can access the live webcast and replay via the company's website.
Palvella Therapeutics' upcoming Q3 2026 financial results and corporate update provide context for health sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 95 rose and 47 fell. Notable movers include HLN at USD 8.58 with a 1-day change of -14.20% and a typical hold time of 15 days, TDOC at USD 7.83 up 13.81% with a typical hold time of 39 days, and IOVA at USD 13.40 down 9.52% with a typical hold time of 5 days and Pluang order activity showing 100% sell and 0% buy.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
